8-K: bioAffinity's CyPath Lung Test Shines at Cancer Roundtable

bioAffinity Technologies announced its CyPath Lung test successfully identified early-stage lung cancer in challenging cases, to be presented at the American Cancer Society National Lung Cancer Roundtable.

Summary

• bioAffinity Technologies will present a poster on its CyPath Lung test at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.
• The poster, titled "CyPath Lung in Practice: From Uncertainty to Clarity and Confidence," will be presented by Chief Medical Officer Dr. Gordon Downie.
• It showcases three cases where CyPath Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations.
• CyPath Lung provided clarity and actionable results, leading to confirmed diagnoses at the earliest and most treatable stage, even when other diagnostic tools were conflicting.
• The test uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify malignant cell populations in sputum.
• Clinical study results showed CyPath Lung achieved 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters).

Sentiment

Score: 8

Explanation: The filing is highly positive, showcasing the successful application and strong performance metrics of the company's flagship diagnostic product, CyPath Lung, at a significant industry event. It highlights the product's ability to address a critical clinical need for early and accurate lung cancer detection.

Positives

• CyPath Lung successfully identified Stage 1A lung cancer in diagnostically challenging cases, demonstrating its clinical utility.
• The test provides clarity and actionable results, accelerating diagnosis and potentially preventing unnecessary invasive procedures.
• High clinical study results: 92% sensitivity, 87% specificity, and 88% accuracy for early-stage lung cancer detection in high-risk patients.
• Presentation at a prestigious event like the American Cancer Society National Lung Cancer Roundtable increases visibility and credibility for the product.
• The technology incorporates advanced flow cytometry and AI, indicating a modern and robust diagnostic approach.

Risks

• The ability of CyPath Lung to identify lung cancer may differ from current expectations.
• Actual results could differ materially from forward-looking statements due to various risks and uncertainties.
• Other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings could impact future results.

Future Outlook

The company continues to advance noninvasive diagnostics for lung cancer and other lung diseases, with CyPath Lung being a key product. The upcoming presentation aims to highlight its utility in real-world clinical practice, suggesting ongoing efforts to integrate it into diagnostic pathways and improve patient outcomes.

Management Comments

• "Indeterminate pulmonary nodules pose a significant and growing clinical burden, especially when clinicians are confronted with conflicting or inconclusive diagnostic data." Dr. Gordon Downie, Chief Medical Officer.
• "Risk calculators, imaging, genetic testing, and biomarker tools can at times point in opposing directions, leaving clinicians and patients uncertain about next steps." Dr. Gordon Downie.
• "These three cases illustrate scenarios that are increasingly common in real-world lung nodule practice." Dr. Gordon Downie.
• "Incorporating CyPath Lung into the diagnostic pathway can accelerate diagnosis, guide difficult conversations with anxious patients, and prevent unnecessary invasive procedures that carry their own risks." Dr. Gordon Downie.

Industry Context

The announcement highlights the growing clinical burden of indeterminate pulmonary nodules and the challenges clinicians face with conflicting diagnostic data. CyPath Lung positions itself as a solution to provide clarity and accelerate diagnosis in this complex area, aligning with the broader trend towards earlier, less invasive, and more accurate cancer detection methods. The American Cancer Society National Lung Cancer Roundtable is a significant forum for addressing lung cancer mortality, indicating the relevance of bioAffinity's work within the industry.

Comparison to Industry Standards

• The filing implicitly compares CyPath Lung's performance to other diagnostic tools (risk calculators, imaging, genetic testing, biomarker tools, bronchoscopy, blood serum marker tests) by stating that CyPath Lung provided clarity when these tools were conflicting or inconclusive.
• CyPath Lung's reported 92% sensitivity, 87% specificity, and 88% accuracy for early-stage lung cancer detection in high-risk patients with small lung nodules (less than 20mm) are strong metrics for a noninvasive test in a field where early detection is critical for improved outcomes.

Stakeholder Impact

• Shareholders: Positive impact due to increased visibility and validation of the company's core product, potentially leading to increased investor confidence.
• Patients: Positive impact through the potential for earlier, more accurate, and less invasive diagnosis of lung cancer, leading to improved treatment outcomes.
• Clinicians: Provides a valuable tool to address diagnostic challenges with indeterminate pulmonary nodules, offering clarity and guiding treatment decisions.
• Employees: Positive impact through the successful advancement and recognition of the company's technology.

Next Steps

• Chief Medical Officer Dr. Gordon Downie will present the poster "CyPath Lung in Practice: From Uncertainty to Clarity and Confidence" at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025.
• The poster will be made available for viewing on the bioAffinity website.
• Continued marketing of CyPath Lung as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services.

Key Dates

Recommendation

While the news is positive, highlighting the clinical utility and strong performance of CyPath Lung, it is an announcement of a presentation rather than a new financial result or a major commercial milestone. The information reinforces the company's value proposition but does not present a new catalyst for a significant re-rating. Investors would likely hold to observe the commercial adoption and financial impact of the product.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer, noninvasive diagnostic, flow cytometry, artificial intelligence, early-stage cancer, biotechnology, cancer detection, medical device, diagnostic test, sputum test, pulmonary nodules, American Cancer Society